Lewy Body Disease - Pipeline Insight, 2024

Lewy Body Disease - Pipeline Insight, 2024

DelveInsight’s, “Lewy Body Disease - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Lewy Body Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Lewy Body Disease: Understanding

Lewy Body Disease: Overview

Lewy Body Disease (LBD) is caused by the degeneration and death of nerve cells in the brain. The name comes from the presence of abnormal spherical structures, called Lewy bodies, which develop inside nerve cells. It is thought that these may contribute to the death of the brain cells. They are named after the doctor who first wrote about them. It is sometimes referred to as Diffuse Lewy Body Disease. At present there is no known cause of Lewy Body Disease, and no known risk factors have been identified. There is no evidence that it is an inherited disease.

Symptoms such as depression and disturbing hallucinations can usually be reduced by medication. However, medications to relieve hallucinations may increase muscle tremors and stiffness. Conversely, anti-Parkinson drugs may make hallucinations worse. Other symptoms include movement disorders, poor regulation of body functions, cognitive problems, and trouble with sleep, varying attention, and depression. These Lewy bodies are primarily found in the cerebral cortex and substantia nigra, regions critical for cognitive function and movement regulation. The pathology of LBD involves widespread neurodegeneration, leading to a progressive decline in cognitive abilities, motor dysfunction, and a range of neuropsychiatric symptoms, including visual hallucinations and fluctuating attention. The presence of Lewy bodies disrupts normal cellular function, impairs synaptic transmission, and ultimately results in neuronal death. The exact cause of alpha-synuclein aggregation remains unclear, but genetic, environmental, and age-related factors are believed to contribute to the disease process.

There is no cure for Lewy body dementia, but many of the symptoms can improve with targeted treatments. Medications include Cholinesterase inhibitors these Alzheimer's disease medicines work by increasing the levels of chemical messengers in the brain, known as neurotransmitters, Parkinson's disease medicines. Medicines such as carbidopa-levodopa (Sinemet, Duopa, others) can help reduce rigid muscles and slow movement. Certain medicines can worsen memory. Therapies antipsychotic medicines can worsen Lewy body dementia symptoms. It might be helpful to first try other approaches, such as: Tolerating the behavior. Some people with Lewy body dementia aren't distressed by the hallucinations. Modifying the environment and reducing clutter and noise can make it easier for someone with dementia to function and lastly by creating daily routines and keeping tasks simple break tasks into easier steps and focus on successes, not failures. Structure and routine during the day can be less confusing.
 
""Lewy Body Disease- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lewy Body Disease pipeline landscape is provided which includes the disease overview and Lewy Body Disease treatment guidelines. The assessment part of the report embraces, in depth Lewy Body Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lewy Body Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lewy Body Disease R&D. The therapies under development are focused on novel approaches to treat/improve Lewy Body Disease.

Lewy Body Disease Emerging Drugs Chapters

This segment of the Lewy Body Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lewy Body Disease Emerging Drugs

LY3154207: Eli Lilly and Company

Mevidalen (LY3154207) is a selective and orally active D1-positive allosteric modulator with >1000-fold selectivity for the human D1 receptor over other tested targets. Mevidalen increases the extracellular level of acetylcholine in the prefrontal cortex and enhances the affinity of dopamine for the D1 receptor. This amplifies the responses to endogenous and exogenous dopamine, which may improve motor and cognitive symptoms of Parkinson Disease and Lewy body dementias as well as sleepiness, mood, and apathy. Currently, the drug is in Phase II stage of its clinical trial evaluation for the treatment of Lewy Body Disease.

Neflamapimod: CervoMed, Inc.

Neflamapimod is an investigational drug that is a brain-penetrant, oral small molecule that inhibits the intra-cellular enzyme p38 MAP kinase alpha (p38α). P38α, which is expressed in neurons under conditions of stress and disease, plays a major role in inflammation-induced synaptic toxicity, leading to impairment of synaptic function. Neflamapimod targets and inhibits p38 alpha, a cellular enzyme linked to the inflammation and synaptic dysfunction that cause neurological disease progression. Currently, the drug is in Phase II stage of its clinical trial evaluation for the treatment of Lewy body disease.

UB 312: Vaxxinity

UB 312 targets toxic forms of aggregated α-synuclein in the brain to fight Parkinson’s and other synucleinopathies, such as dementia with Lewy Body (“DLB”) and multiple system atrophy (“MSA”). The first part of a Phase I trial in healthy volunteers has shown UB-312 to be well tolerated, with no significant safety findings, and immunogenic, with a high responder rate and antibodies that cross the blood-brain barrier (“BBB”). Currently, the drug is in Phase I stage of its development for the treatment of Lewy body disease.

Further product details are provided in the report……..

Lewy Body Disease: Therapeutic Assessment

This segment of the report provides insights about the different Lewy Body Disease drugs segregated based on following parameters that define the scope of the report, such as:

MajorPlayers in Lewy Body Disease

There are approx. 10+ key companies which are developing the therapies for Lewy Body Disease. The companies which have their Lewy Body Disease drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company and CervoMed, Inc.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Lewy Body Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lewy Body Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Lewy Body Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lewy Body Disease drugs.

Lewy Body Disease Report Insights

Lewy Body Disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Lewy Body Disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Lewy Body Disease drugs?

How many Lewy Body Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lewy Body Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lewy Body Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Lewy Body Disease and their status?

What are the key designations that have been granted to the emerging drugs?
 
Key Players

Annovis Bio

CervoMed, Inc

Vaxxinity

Eisai Inc.

Cognition Therapeutics

Eli Lilly and Company

Athira Pharma

NLS Pharmaceutics

Key Products

Buntanetap

Neflamapimod

UB 312

E2027

CT1812

LY3154207

ATH-1017

Oxafuramine